NMNAT1 — Nicotinamide nucleotide adenylyltransferase 1

The NMNAT1 gene provides instructions for making an enzyme that is essential for producing a molecule called NAD+ in the nucleus of cells. NAD+ is crucial for many cellular processes, including DNA repair and cell survival. In the eye, this enzyme is particularly important for the development and survival of light-sensing cells called photoreceptors. When there are mutations in the NMNAT1 gene, the enzyme does not work properly, leading to a shortage of NAD+ in the nucleus. This deficiency causes the light-sensing cells in the retina to degenerate rapidly, leading to a condition called Leber congenital amaurosis 9 (LCA9). Patients with this condition typically experience severe vision loss or blindness starting in the first few years of life. The disease is characterized by a specific type of damage to the central part of the retina, known as macular coloboma, which severely affects central vision.

Gene description: NMNAT1 encodes a nuclear NAD(+) synthase that catalyzes a key step in NAD biosynthesis by converting nicotinamide mononucleotide and ATP into NAD(+). Mutations in this gene are associated with Leber congenital amaurosis 9, a severe blinding disease.

Patient and family guide: The NMNAT1 gene provides instructions for making an enzyme that is essential for producing a molecule called NAD+ in the nucleus of cells. NAD+ is crucial for many cellular processes, including DNA repair and cell survival. In the eye, this enzyme is particularly important for the development and survival of light-sensing cells called photoreceptors. When there are mutations in the NMNAT1 gene, the enzyme does not work properly, leading to a shortage of NAD+ in the nucleus. This deficiency causes the light-sensing cells in the retina to degenerate rapidly, leading to a condition called Leber congenital amaurosis 9 (LCA9). Patients with this condition typically experience severe vision loss or blindness starting in the first few years of life. The disease is characterized by a specific type of damage to the central part of the retina, known as macular coloboma, which severely affects central vision.

Gene function: NMNAT1 is a nuclear-localized enzyme that catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. It is the convergent step of all mammalian NAD+ biosynthetic pathways and is crucial for proper differentiation of retinal neurons and maintaining nuclear NAD+ homeostasis.

Protein structure: Wild type NMNAT1 shows a circular dichroism (CD) spectrum typical of an alpha-helical-rich protein. It migrates with an apparent molecular mass of 33 kD.

Molecular function: NMNAT1 catalyzes the final and rate-limiting step in NAD+ biosynthesis, thereby providing a nuclear pool of NAD+. It catalyzes the adenylation of nicotinamide mononucleotide (NMN) or nicotinic acid mononucleotide (NaMN) to form NAD+. The nuclear NAD+ pool is important to many cellular processes, including those related to DNA repair, gene expression, cell signaling, and cell senescence. Activity of this protein leads to the activation of a nuclear deacetylase that functions in the protection of damaged neurons.

Mutation spectrum: Mutations in NMNAT1 include missense mutations (e.g., E257K, V9M), nonsense mutations (e.g., W169X), and read-through mutations (e.g., X280Q). Over 34 mutations in NMNAT1 are associated with retinal degeneration, each of which is presumed to decrease enzymatic activity to varying degrees.

Clinical significance: Mutations in the NMNAT1 gene cause severe and rapidly progressive macular degeneration, leading to severe central atrophy with an appearance of congenital macular coloboma in the neonatal period, as well as an unusual early-onset atrophy of the optic nerve. This results in Leber congenital amaurosis 9 (LCA9), an early-onset, recessive disease that causes severe vision loss during the first or second decade of life. A syndromic form of LCA (SHILCA) is also caused by mutations in the NMNAT1 gene. The loss of NMNAT1 leads to early and severe retinal degeneration, particularly affecting photoreceptors and select inner retinal neurons via multiple distinct cell death pathways.

Inheritance: Autosomal Recessive

Chromosomal location: 1p36.22

Research and therapeutic approaches: Currently, no treatment exists for NMNAT1-associated retinal degeneration. However, gene augmentation therapy using adeno-associated virus (AAV) vectors is being investigated. In mouse models, subretinal injection of AAV carrying a normal human copy of NMNAT1 (e.g., SC.AAV2/9) has been shown to rescue retinal structure and function, suggesting that AAV-mediated gene therapy has the potential to benefit patients.